B
Biolevate
Biolevate is a VC-backed B2B startup harnessing the power of AI to deliver therapeutics innovation faster to market thanks to an all-in-one SaaS platform
About Biolevate
Biolevate operates at the intersection of artificial intelligence and healthcare, providing specialized B2B solutions to the pharmaceutical, MedTech, and cosmetics industries. The company leverages a combination of AI technology and human expertise to accelerate medical advancements in a safe and ethical manner. Its core offerings are designed to support the entire development lifecycle of healthcare products, from preclinical research to clinical trials and regulatory compliance.
Read full description
The company's service suite includes AI-assisted drug discovery and development, tools for personalized medicine, and intelligent management of clinical and regulatory data. Key features of its platform are research and literature monitoring, advanced search capabilities with customizable filters, and AI-driven insights that help clients prioritize relevant data. By enhancing the efficiency of R&D processes and improving regulatory compliance, Biolevate aims to reduce the time-to-market for new healthcare innovations.
Founded by a team of experts in AI and life sciences, the company is committed to responsible innovation, data privacy, and the seamless integration of its AI technology into client workflows. While currently focused on serving businesses, Biolevate is also developing future applications for hospitals and healthcare providers to address the evolving needs of the healthcare landscape.
At a glance
- Status
- Operational
- Founded
- 2024
- Headquarters
- Paris, France
- Employees
- 36
- Open positions
- 8
- Dealroom signal
- 87.1/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Medical Education, Clinical, Clinical Decision Support, Physician Support Tools, AI Drug Discovery, biotech medtech and e-health, Observatoire Deeptech
- Technology
- Artificial Intelligence
- Business model
- SaaS
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Biolevate.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Nov 2024 | $6.6M | $26M | Bpifrance · Mehdi Ghissassi · EQT Ventures | ↗ |
Growth signals
Latest recorded traffic for Biolevate is 4.3K monthly website visits, up 207.1% over the last three months. Biolevate's team grew 24.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
EQT Ventures
Bpifrance- MGMehdi Ghissassi
Other known investors1 additional known investor
Future4Care
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Biolevate on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biolevate’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.